Aptar Pharma subsidiary Noble has launched a suite of services for makers of combination products such as OINDPs under the “Human Factors Plus” (HF+) brand. Noble, which was acquired by Aptar Pharma in 2019, makes respiratory and intranasal training devices and patient onboarding platforms. The HF+ umbrella includes a number of services related to regulatory strategy, evaluation of human factors characteristics, and device design.
Noble Senior Research Human Factors Engineer Kevin Cluff said, “Human factors engineering provides empirical and analytical evidence that a device and its labeling can be used safely and effectively by the intended patient. This process involves testing the numerous touch points where patients interface with a drug product, including packaging, IFUs, prescribing information, quick reference guides and device indicators and controls.”
Executive Director of Marketing and Patient Services Tim McLeroy commented, “We understand how to leverage the application of human factors engineering and we know how to build a better patient experience. Together, HF+ engineering and building a better patient experience are a powerful combination to support product development and FDA approval for our customers and their combination products.”
Read the Noble press release.
